NCT03678883 2026-04-03
9-ING-41 in Patients With Advanced Cancers
Actuate Therapeutics Inc.
Phase 2 Active not recruiting
Clinical Trials
53 trialsNCT06450041 2026-03-23
NANT 2021-01 Phase II STING (Sequential Temozolomide, Irinotecan, NK Cells and GD2 mAb) Trial
New Approaches to Neuroblastoma Therapy Consortium
Phase 2 Recruiting
NCT01356290 2026-02-23
MEMMAT
Medical University of Vienna
Phase 2 Recruiting
NCT03794349 2026-02-18
Irinotecan Hydrochloride, Temozolomide, and Dinutuximab With or Without Eflornithine in Treating Patients With Relapsed or Refractory Neuroblastoma
Children's Oncology Group
Phase 2 Active not recruiting
NCT06528496 2026-02-10
N10: A Study of Reduced Chemotherapy and Monoclonal Antibody (mAb)-Based Therapy in Children With Neuroblastoma
Memorial Sloan Kettering Cancer Center
Phase 2 Recruiting
NCT04743661 2026-02-05
131I-Omburtamab, in Recurrent Medulloblastoma and Ependymoma
Pediatric Brain Tumor Consortium
Phase 2 Active not recruiting
NCT07318831 2026-01-06
Phase II Study of Chidamide-Dinutuximab Beta-Irinotecan-Temozolomide for Refractory/Relapsed Neuroblastoma in Children
Tianjin Medical University Cancer Institute and Hospital
Phase 2 Not yet recruiting
NCT04385277 2025-10-27
Treatment With Dinutuximab, Sargramostim (GM-CSF), and Isotretinoin in Combination With Irinotecan and Temozolomide After Intensive Therapy for People With High-Risk Neuroblastoma (NBL)
Children's Oncology Group
Phase 2 Active not recruiting
NCT06013618 2025-06-17
Clinical Analysis of Naxitamab (hu3F8) in the Treatment of Pediatric High Risk or Refractory/ Relapsed Neuroblastoma
Sun Yat-sen University
Phase 2 Recruiting
NCT03709680 2025-01-14
Study Of Palbociclib Combined With Chemotherapy In Pediatric Patients With Recurrent/Refractory Solid Tumors
Pfizer
Phase 2 Active not recruiting
NCT02308527 2024-05-14
BEACON
University of Birmingham
Phase 2 Active not recruiting
NCT01767194 2022-10-24
Irinotecan Hydrochloride and Temozolomide With Temsirolimus or Dinutuximab in Treating Younger Patients With Refractory or Relapsed Neuroblastoma
National Cancer Institute (NCI)
Phase 2 Completed
NCT02035137 2022-06-08
N2011-01
New Approaches to Neuroblastoma Therapy Consortium
Phase 2 Completed
NCT01012609 2022-03-14
External Beam Radiation Therapy and Cetuximab Followed by Irinotecan and Cetuximab for Children and Young Adults With Newly Diagnosed Diffuse Pontine Tumors and High-Grade Astrocytomas
Memorial Sloan Kettering Cancer Center
Phase 2 Completed
NCT01217437 2021-07-23
Temozolomide and Irinotecan Hydrochloride With or Without Bevacizumab in Treating Young Patients With Recurrent or Refractory Medulloblastoma or CNS Primitive Neuroectodermal Tumors
National Cancer Institute (NCI)
Phase 2 Completed
NCT01467986 2020-10-06
RIST-rNB-2011
University of Regensburg
Phase 2 Completed
NCT01114555 2019-11-21
Bevacizumab, Irinotecan and Temozolomide for Relapsed or Refractory Neuroblastoma
Memorial Sloan Kettering Cancer Center
Phase 2 Completed
NCT00433381 2018-09-17
Bevacizumab and Irinotecan or Temozolomide in Treating Patients With Recurrent or Refractory Glioblastoma Multiforme or Gliosarcoma
National Cancer Institute (NCI)
Phase 2 Completed
NCT00617539 2018-04-20
Irinotecan and Temozolomide in Treating Patients With Breast Cancer Who Have Received Previous Treatment for Brain Metastases
University of California, San Francisco
Phase 2 Completed
NCT00381797 2017-11-28
Bevacizumab and Irinotecan in Treating Young Patients With Recurrent, Progressive, or Refractory Glioma, Medulloblastoma, Ependymoma, or Low Grade Glioma
National Cancer Institute (NCI)
Phase 2 Completed
NCT00808899 2017-05-30
Neuroblastoma Protocol 2008: Therapy for Children With Advanced Stage High Risk Neuroblastoma
St. Jude Children's Research Hospital
Phase 2 Terminated
NCT00345163 2017-05-16
BRAIN
Genentech, Inc.
Phase 2 Completed
NCT00360828 2017-03-23
Phase II Study of Irinotecan HCI for Recurrent Anaplastic Astrocytomas, Mixed Malignant Gliomas, and Oligodendrogliomas
H. Lee Moffitt Cancer Center and Research Institute
Phase 2 Terminated
NCT00003134 2016-12-07
Irinotecan in Treating Patients With Recurrent Glioma
Alliance for Clinical Trials in Oncology
Phase 2 Completed
NCT02060955 2016-06-06
Randomized Phase 2 Study to Investigate Efficacy of ALECSAT in Patients With GBM Measured Compared to Avastin/Irinotecan
CytoVac A/S
Phase 2 Terminated
NCT01173497 2016-03-17
A Study Evaluating INIPARIB in Combination With Chemotherapy to Treat Triple Negative Breast Cancer Brain Metastasis
Sanofi
Phase 2 Completed
NCT00967330 2015-11-20
A Study of Avastin (Bevacizumab) and Irinotecan Versus Temozolomide Radiochemistry in Patients With Glioblastoma
Hoffmann-La Roche
Phase 2 Completed
NCT01574092 2015-08-24
Irinotecan in Combination With Cisplatin in Pediatric Patients With Unfavorable Prognosis Gliomas
Hospital Sant Joan de Deu
Phase 2 Completed
NCT00311584 2014-09-30
Irinotecan and Temozolomide in Treating Young Patients With Recurrent Neuroblastoma
Children's Oncology Group
Phase 2 Completed
NCT00616005 2014-08-18
Ph. II Treatment of Adults w Primary Malignant Glioma w Irinotecan + Temozolomide
Duke University
Phase 2 Completed
NCT00352521 2014-07-22
Dynamic Contrast-Enhanced Magnetic Resonance Imaging (DCE-MRI) With Bevacizumab and Irinotecan for Malignant Glioma
Duke University
Phase 2 Completed
NCT00268359 2014-07-21
Bevacizumab and Irinotecan in Treating Patients With Recurrent or Refractory Gliomas
Duke University
Phase 2 Completed
NCT01535183 2014-07-14
Irinotecan Combination Chemotherapy for Refractory or Relapsed Brain Tumor in Children and Adolescents
Seoul National University Hospital
Phase 2 Unknown
NCT00597402 2014-05-07
Avastin in Combination With Radiation (XRT) & Temozolomide, Followed by Avastin, Temozolomide and Irinotecan for Glioblastoma (GBM) and Gliosarcomas
Duke University
Phase 2 Completed
NCT00979017 2014-03-19
Avastin/Temozolomide/Irinotecan for Unresectable/Multifocal Glioblastoma Multiforme
Duke University
Phase 2 Completed
NCT00099125 2014-01-24
Radiation Therapy, Temozolomide, and Irinotecan in Treating Patients With Newly Diagnosed Glioblastoma Multiforme
Radiation Therapy Oncology Group
Phase 2 Completed
NCT00921167 2013-12-04
A Study to Evaluate the Efficacy of Bevacizumab Plus Irinotecan in Recurrent Gliomas
Clinical Research Center for Solid Tumor, Korea
Phase 2 Completed
NCT00953121 2013-09-16
Bevacizumab Plus Irinotecan Plus Carboplatin for Recurrent Malignant Glioma (MG)
Duke University
Phase 2 Completed
NCT01017653 2013-09-04
Panitumumab and Irinotecan for Malignant Gliomas
Duke University
Phase 2 Terminated
NCT00004078 2013-06-14
Irinotecan in Treating Children With Refractory Solid Tumors
Children's Oncology Group
Phase 2 Completed
NCT00735436 2013-02-11
A Study of Gliadel Followed by Avastin + Irinotecan for Glioblastoma Multiforme (GBM)
Duke University
Phase 2 Terminated
NCT00393094 2012-07-13
Bevacizumab and Irinotecan to Treat Brain Tumors
National Institutes of Health Clinical Center (CC)
Phase 2 Terminated
NCT00404495 2012-04-18
Combination of Irinotecan and Temozolomide in Children With Brain Tumors.
Pfizer
Phase 2 Completed
NCT00412542 2012-02-28
Thalidomide and Temozolomide or Camptothecin-11 (CPT-11) in Patients With Gliomas
M.D. Anderson Cancer Center
Phase 2 Completed
NCT00817284 2011-11-30
Bevacizumab and Irinotecan or Bevacizumab and Temozolomide With Concomitant Radiotherapy for Primary Glioblastoma Multiforme (GBM)
Rigshospitalet, Denmark
Phase 2 Completed
NCT00039468 2011-10-27
Thalidomide and Irinotecan in Treating Patients With Glioblastoma Multiforme Who Have Undergone Radiation Therapy
Dartmouth-Hitchcock Medical Center
Phase 2 Completed
NCT00004068 2011-10-04
Irinotecan Followed by Radiation Therapy and Temozolomide in Treating Children With Newly Diagnosed Brain Tumor
St. Jude Children's Research Hospital
Phase 2 Completed
NCT01144988 2011-08-02
AVIRMA01-09
Medical University Innsbruck
Phase 2 Unknown
NCT00463203 2011-06-29
Bevacizumab and Irinotecan for Patients With Primary Brain Tumors and Progression After Standard Therapy
Rigshospitalet, Denmark
Phase 2 Completed
NCT00010036 2011-03-28
Carboplatin Plus Irinotecan in Treating Patients With Glioblastoma Multiforme
NYU Langone Health
Phase 2 Completed